The discovery and development of sorafenib for the treatment of thyroid cancer

Bibliography

• Howlader N, Noone AM, Krapcho M, et al., editors. SEER Cancer Statistics Review, 1975-2011. National Cancer Institute, Bethesda, MD; Available from: http://seer.cancer.gov/csr/1975_2011/; based on November 2013 SEER data submission, posted to the SEER web site, April 2014
   Google Scholar
• Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National cancer data base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see commetns]. Cancer 1998;83:2638-48
   PubMed Web of Science ®Google Scholar
• Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006;295:2164-7
   PubMed Web of Science ®Google Scholar
• Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19:1167-214
   PubMed Web of Science ®Google Scholar
• Mazzaferri EL, Massoll N. Management of papillary and follicular (differentiated) thyroid cancer: new paradigms using recombinant human thyrotropin. Endocr Relat Cancer 2002;9:227-47
   PubMed Web of Science ®Google Scholar
• Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994;97:418-28
   PubMed Web of Science ®Google Scholar
• Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006;91:2892-9
   PubMed Web of Science ®Google Scholar
• Xing M, Haugen BR, Schlumberger M. Progress in molecular-based management of differentiated thyroid cancer. Lancet 2013;381:1058-69
   PubMed Web of Science ®Google Scholar
• Sherman SI. Cytotoxic chemotherapy for differentiated thyroid carcinoma. Clin Oncol (R Coll Radiol) 2010;22:464-8
   PubMed Web of Science ®Google Scholar
• Hoshino R, Chatani Y, Yamori T, et al. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 1999;18:813-22
   PubMed Web of Science ®Google Scholar
• MacCorkle RA, Tan TH. Mitogen-activated protein kinases in cell-cycle control. Cell Biochem Biophys 2005;43:451-61
   PubMed Web of Science ®Google Scholar
• Robinson MJ, Cobb MH. Mitogen-activated protein kinase pathways. Curr Opin Cell Biol 1997;9:180-6
   PubMed Web of Science ®Google Scholar
• Santoro M, Melillo RM, Fusco A. RET/PTC activation in papillary thyroid carcinoma: european Journal of Endocrinology Prize Lecture. Eur J Endocrinol 2006;155:645-53
   PubMed Web of Science ®Google Scholar
• Zhu Z, Ciampi R, Nikiforova MN, et al. Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity. J Clin Endocrinol Metab 2006;91:3603-10
   PubMed Web of Science ®Google Scholar
• Xing M, Westra WH, Tufano RP, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 2005;90:6373-9
   PubMed Web of Science ®Google Scholar
• Xing M, Alzahrani AS, Carson KA, et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA 2013;309:1493-501
   PubMed Web of Science ®Google Scholar
• Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 2007;28:742-62
   PubMed Web of Science ®Google Scholar
• Pak K, Suh S, Kim SJ, Kim IJ. Prognostic value of genetic mutations in thyroid cancer: a meta-analysis. Thyroid 2015;25(1):63-70
   PubMed Web of Science ®Google Scholar
• Hou P, Liu D, Shan Y, et al. Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res 2007;13:1161-70
   PubMed Web of Science ®Google Scholar
• Zou M, Baitei EY, Alzahrani AS, et al. Concomitant RAS, RET/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma. Thyroid 2014;24:1256-66
   PubMed Web of Science ®Google Scholar
• Wilhelm S, Carter C, Lynch M, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006;5:835-44
   PubMed Web of Science ®Google Scholar
• Smith RA, Barbosa J, Blum CL, et al. Discovery of heterocyclic ureas as a new class of raf kinase inhibitors: identification of a second generation lead by a combinatorial chemistry approach. Bioorg Med Chem Lett 2001;11:2775-8
   PubMed Web of Science ®Google Scholar
• Lyons JF, Wilhelm S, Hibner B, Bollag G. Discovery of a novel Raf kinase inhibitor. Endocr Relat Cancer 2001;8:219-25
   PubMed Web of Science ®Google Scholar
• Wilhelm S, Chien DS. BAY 43-9006: preclinical data. Curr Pharm Des 2002;8:2255-7
   PubMed Web of Science ®Google Scholar
• Lowinger TB, Riedl B, Dumas J, Smith RA. Design and discovery of small molecules targeting raf-1 kinase. Curr Pharm Des 2002;8:2269-78
   PubMed Web of Science ®Google Scholar
• Wan PT, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004;116:855-67
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109
   PubMed Web of Science ®Google Scholar
• Carlomagno F, Anaganti S, Guida T, et al. BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 2006;98:326-34
   PubMed Web of Science ®Google Scholar
• Sharma A, Trivedi NR, Zimmerman MA, et al. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res 2005;65:2412-21
   PubMed Web of Science ®Google Scholar
• Salvatore G, De Falco V, Salerno P, et al. BRAF is a therapeutic target in aggressive thyroid carcinoma. Clin Cancer Res 2006;12:1623-9
   PubMed Web of Science ®Google Scholar
• Fallahi P, Ferrari SM, Santini F, et al. Sorafenib and thyroid cancer. BioDrugs 2013;27:615-28
   PubMed Web of Science ®Google Scholar
• Kim S, Yazici YD, Calzada G, et al. Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Mol Cancer Ther 2007;6:1785-92
   PubMed Web of Science ®Google Scholar
• Schweppe RE, Klopper JP, Korch C, et al. Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab 2008;93:4331-41
   PubMed Web of Science ®Google Scholar
• Strumberg D, Richly H, Hilger RA, et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005;23:965-72
   PubMed Web of Science ®Google Scholar
• Clark JW, Eder JP, Ryan D, et al. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 2005;11:5472-80
   PubMed Web of Science ®Google Scholar
• Awada A, Hendlisz A, Gil T, et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 2005;92:1855-61
   PubMed Web of Science ®Google Scholar
• Moore M, Hirte HW, Siu L, et al. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 2005;16:1688-94
   PubMed Web of Science ®Google Scholar
• Strumberg D, Awada A, Hirte H, et al. Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: is rash associated with treatment outcome? Eur J Cancer 2006;42:548-56
   PubMed Web of Science ®Google Scholar
• Strumberg D, Clark JW, Awada A, et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 2007;12:426-37
   PubMed Web of Science ®Google Scholar
• Kane RC, Farrell AT, Saber H, et al. Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res 2006;12:7271-8
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009;27:3312-18
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Porta C, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23(Suppl 7):vii65-71
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90
   PubMed Web of Science ®Google Scholar
• Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011;53(3):1020-2
   PubMed Web of Science ®Google Scholar
• Gupta-Abramson V, Troxel AB, Nellore A, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008;26:4714-19
   PubMed Web of Science ®Google Scholar
• Kloos RT, Ringel MD, Knopp MV, et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009;27:1675-84
   PubMed Web of Science ®Google Scholar
• Lam ET, Ringel MD, Kloos RT, et al. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol 2010;28:2323-30
   PubMed Web of Science ®Google Scholar
• Ahmed M, Barbachano Y, Riddell A, et al. Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population. Eur J Endocrinol 2011;165:315-22
   PubMed Web of Science ®Google Scholar
• Savvides P, Nagaiah G, Lavertu P, et al. Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid. Thyroid 2013;23:600-4
   PubMed Web of Science ®Google Scholar
• Thomas L, Lai SY, Dong W, et al. Sorafenib in metastatic thyroid cancer: a systematic review. Oncologist 2014;19:251-8
   PubMed Web of Science ®Google Scholar
• Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 2014;384:319-28
   PubMed Web of Science ®Google Scholar
• Brose MS, Jarzab B, Elisei R, et al. Updated overall survival analysis of patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) treated with sorafenib on the phase 3 DECISION trial. Abstract from ASCO Annual Meeting J Clin Oncol 2014;32(5 Suppl):abstract 6060^
   Google Scholar
• Capdevila J, Iglesias L, Halperin I, et al. Sorafenib in metastatic thyroid cancer. Endocr Relat Cancer 2012;19:209-16
   PubMed Web of Science ®Google Scholar
• Hoftijzer H, Heemstra KA, Morreau H, et al. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol 2009;161:923-31
   PubMed Web of Science ®Google Scholar
• Schneider TC, Abdulrahman RM, Corssmit EP, et al. Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial. Eur J Endocrinol 2012;167:643-50
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhou Q, Ma L, et al. Meta-analysis of dermatological toxicities associated with sorafenib. Clin Exp Dermatol 2011;36:344-50
   PubMed Web of Science ®Google Scholar
• Azad NS, Aragon-Ching JB, Dahut WL, et al. Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. Clin Cancer Res 2009;15:1411-16
   PubMed Web of Science ®Google Scholar
• Boudou-Rouquette P, Ropert S, Mir O, et al. Variability of sorafenib toxicity and exposure over time: a pharmacokinetic/pharmacodynamic analysis. Oncologist 2012;17:1204-12
   PubMed Web of Science ®Google Scholar
• Bayer HealthCare Pharmaceuticals. NEXAVAR Prescribing Information [online]. Bayer HealthCare Pharmaceuticals, Inc., Whippany, NJ; 2013. Available from: http://labeling.bayerhealthcare.com/html/products/pi/Nexavar_PI.pdf
   Google Scholar
• Ghassabian S, Rawling T, Zhou F, et al. Role of human CYP3A4 in the biotransformation of sorafenib to its major oxidized metabolites. Biochem pharmacol 2012;84:215-23
   PubMed Web of Science ®Google Scholar
• Miller AA, Murry DJ, Owzar K, et al. Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol 2009;27:1800-5
   PubMed Web of Science ®Google Scholar
• Schlumberger M, Jarzab B, Elisei R, et al. Phase III randomized, double-blinded, placebo controlled trial of sorafenib in locally advanced or metastatic patients with radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC) - exploratory analysis of patient-reported outcomes. Abstract from 83rd ATA meeting 2013. Thyroid 2013;23(S1):A-1-A-114
   Google Scholar
• Worden FP, Fassnacht M, Yuankai S, et al. Safety and tolerability of sorafenib for treatment of locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC): Detailed analyses from the phase III DECISION trial. Abstract from ASCO annual meeting. J Clin Oncol 2014;32(5 Suppl):abstract 6062^
   Google Scholar
• Marotta V, Ramundo V, Camera L, et al. Sorafenib in advanced iodine-refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET. Clin Endocrinol 2013;78:760-7
   PubMed Web of Science ®Google Scholar
• Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 2007;96:1788-95
   PubMed Web of Science ®Google Scholar
• Je Y, Schutz FA, Choueiri TK. Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. Lancet Oncol 2009;10:967-74
   PubMed Web of Science ®Google Scholar
• Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 2007;7:332-44
   PubMed Web of Science ®Google Scholar
• Arnault JP, Mateus C, Escudier B, et al. Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1. Clin Cancer Res 2012;18:263-72
   PubMed Web of Science ®Google Scholar
• RED BOOK online® product details for Nexavar. Average wholesale price per unit. Online through Micromedex® 2.0. Available from: http://micromedex.com/products/product-suites/clinical-knowledge/redbook. [Last accessed 28 October 2014]
   Google Scholar
• Sherman EJ, Ho AL, Fury MG, et al. Phase II study of everolimus and sorafenib for the treatment of metastatic thyroid cancer. Abstract from ASCO annual meeting. J Clin Oncol 2013;31(Suppl):6024
   Google Scholar
• Phase II study evaluating the combination of temsirolimus and sorafenib in the treatment of radioactive iodine refractory thyroid cancer. Available from: ClinicalTrials.gov study identifier NC01025453 [Last accessed 28 October 2014]
   Google Scholar
• Schlumberger M, Tahara M, Wirth LJ, et al. A phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid cancer (SELECT). Abstract from ASCO Annual Meeting. J Clin Oncol 2014(5 Suppl):abstract LBA6008
   Google Scholar
• Brose MS, Frenette CT, Keefe SM, Stein SM. Management of sorafenib-related adverse events: a clinician’s perspective. Semin Oncol 2014;41(Suppl 2):S1-s16
   PubMedGoogle Scholar
• Bastholt L, Bose MS, Jarzab B, et al. Population PK modeling and exposure-response analyses of sorafenib in patients with radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) in the phase III DECISION trial. Abstract from ASCO Annual Meeting. J Clin Oncol 2014;32(5 Suppl):abstract 6061^
   Google Scholar
• Mir O, Coriat R, Blanchet B, et al. Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma. PLoS One 2012;7:e37563
   PubMed Web of Science ®Google Scholar
• Morimoto M, Numata K, Kondo M, et al. Field practice study of half-dose sorafenib treatment on safety and efficacy for hepatocellular carcinoma: a propensity score analysis. Hepatol Res 2014. 10.1111/hepr.12354
   Web of Science ®Google Scholar
• Agrawal N, Akbani R, Aksoy BA, et al. Integrated genomic characterization of papillary thyroid carcinoma. Cell 2014;159:676-90
   PubMed Web of Science ®Google Scholar